SCH900105 (AV-299) is being developed in collaboration with Schering-Plough. Under the terms of the agreement, human dosing with SCH900105 (AV-299) triggers a $3 million milestone payment from Schering-Plough to Aveo.
Tuan Ha-Ngoc, president and CEO of Aveo, said: “We are pleased to announce the initiation of clinical trials of SCH900105 (AV-299). Working with Schering-Plough, our research teams have made rapid progress with this novel antibody.
“The cMET/ hepatocyte growth factor (HGF) pathway is one of the most promising in cancer research. We believe that SCH900105 (AV-299) has the potential to be the best-in-class anti-HGF antibody. Our proprietary human response platform promises to provide us with tools to move SCH900105 (AV-299) forward rapidly in clinical development.”